ValuentumAd

Official PayPal Seal

Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
May 22, 2017
Investing Versus Speculating: Ford, GM, Tesla
Ford is making some changes at the top, but we still like General Motors. Tesla’s stock remains “uninvestable,” in our view.
May 10, 2017
Large Cap Biotech Earnings Review Featuring Biogen, Celgene, and Gilead Sciences
Image Source: Biogen. The large cap biotech industry remains mired in a downtrend trend since posting a near-term top in the summer of 2015. Growth has clearly slowed and in some cases turned negative--we review the recent earnings reports of some of the largest companies.
May 8, 2017
Alert: Removing Coach; Talking Buffett, Unemployment, and Stock Market Valuations
Image Source: DonkeyHotey.  There are four takeaways from this piece you must know. We’re removing Coach from the Dividend Growth Newsletter portfolio, Buffett may no longer be against paying a dividend at Berkshire, US unemployment now stands at 4.4%, and market valuations remain frothy.
May 8, 2017
Stop Thinking Chronologically and Start Thinking Psychologically
Image Source: Kenzie Saunders.  Let’s cover three important investing prompts, "The Psychology of the Markets," "Dividends Are a Symptom, Not a Driver of Intrinsic Value," and "Don't Revenue and Earnings Have to Advance for Stocks to Go Up?"
May 5, 2017
Dividend Increases/Decreases for the Week Ending May 5
Let's take a look at companies raising/lowering their dividends this week.
May 1, 2017
Big Pharma, Big Dividends: Earnings Update Featuring Eli Lilly, Bristol-Myers Squibb, and AbbVie
Image Source: Drugs.com. Let’s dive into some recent developments and earnings reports from three big pharma players with meaningful income considerations.
Apr 11, 2017
Three Notable Pending FDA Approvals
Image Source: Brandon Giesbrecht. The final step of the drug approval process is the filing of a new drug application (NDA), when the FDA assesses trial results before deciding if the treatment warrants marketing approval. A delay or rejection can have a meaningful impact on the equity price, so let’s dig into a few notable upcoming decisions.
Apr 1, 2017
First Quarter 2017 Comes To A Close
“Be sure to continue to study the difference between price and value—just because a stock’s price has advanced doesn’t make it more expensive if the value of its enterprise has increased at a faster rate. If you understand this concept, you may be smarter than 99.9% of the investing population.” – Brian Nelson, CFA
Mar 30, 2017
Who’s Driving Who: The Future of the Automakers
Image Source: HimmelrichPR. Let’s dig into some recent developments surrounding the auto market, and how technological and strategic innovation could reshape the future of the space.
Mar 30, 2017
Is There Value in DaVita?
Image Source: US Census Bureau. With healthcare the primary focus in Washington, let’s evaluate the investment case for DaVita. We discuss how potential changes can impact the economics of the dialysis market.



The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.